U.S. stock futures were fluctuating on Wednesday following Tuesday’s negative close. Futures of major benchmark indices were mixed.President Donald Trump signed a funding deal to end the four-day partial government shutdown, though the brief closure has already triggered delays for critical economic indicators. Meanwhile, the 10-year Treasury bond yielded 4.27%, and the two-year bond was at 3.58%. The CME Group's FedWatch tool‘s projections show markets pricing a 91.1% likelihood of the Federal Reserve leav ...

For every patient Eli Lilly helped downsize with its obesity drug Zepbound, rival Novo Nordisk’s purse got a little lighter, too. After Novo reported disappointing results Tuesday, all eyes are on Eli’s earnings today, evaluating whether the firm has what it takes to, once and for all, take the Danish firm’s krone. SUBSCRIBE:  Receive more of our free The Daily Upside newsletter. READ ALSO: Molasses-Like Jobs Growth Not Enough to Trump Fed’s Rate-Cut Inertia and Bitcoin Sinks to 14-Month Low amid Plot Tw ...

Market Overview - The three major U.S. stock indices closed lower, with the Dow Jones down 0.34%, the Nasdaq down 1.43%, and the S&P 500 down 0.83% [1] - Popular technology stocks experienced declines, with Broadcom falling over 3%, and Microsoft, Nvidia, and Meta each dropping over 2% [1] Sector Performance - The rare earth, non-ferrous metals, and precious metals sectors saw significant gains, with gold resources rising over 20%, Southern Copper up over 11%, Americas Silver up over 8%, and Pan American Silver up over 5% [1] - Conversely, application software, cryptocurrency, and weight loss drug stocks faced notable declines, with Novo Nordisk down over 14%, Coinbase and Circle each down over 4%, and Eli Lilly and Pfizer each down over 3% [1] Notable Company Movements - Walmart's stock increased by 2.94%, marking its market capitalization surpassing the $1 trillion milestone for the first time [1] - The Nasdaq Golden Dragon China Index fell by 0.94%, with significant declines in popular Chinese stocks such as Daqo New Energy down 5.6%, Bilibili down 4%, and Kingsoft Cloud down 3.5% [1] - Alibaba dropped 2.9%, while NIO rose 0.8%, Pony.ai increased by 2%, Huazhu up 2.2%, New Oriental up 2.3%, Li Auto up 2.7%, Canadian Solar up 4.1%, and Xpeng up 4.3% [1]

Group 1 - The Chinese central bank announced a reverse repurchase operation of 800 billion yuan to maintain liquidity in the banking system, with a term of 3 months [2] - The Shanghai Stock Exchange reported a significant increase in new A-share accounts, with 4.9158 million new accounts opened in January 2026, a month-on-month increase of approximately 89% and a year-on-year increase of about 213% [2] - The Paris prosecutor's office conducted a search of the office of the social media platform X, owned by Elon Musk, as part of an investigation into cybercrime [3] Group 2 - Major U.S. stock indices experienced declines, with the Dow Jones down 0.34%, S&P 500 down 0.84%, and Nasdaq down 1.43%, nearly erasing gains made since the beginning of the year [3][4] - Large technology stocks faced pressure, with Nvidia down 2.84%, Microsoft down 2.87%, and Amazon down 1.79% [4] - The Nasdaq Golden Dragon China Index fell by 0.94%, with Alibaba down 2.81% and Tencent Holdings ADR down 3.33% [4] Group 3 - Commodity markets saw a rebound in gold and silver prices after two days of significant declines, with spot gold rising 5.2% to $4,906.82 per ounce [5] - Crude oil prices slightly rebounded, with WTI crude oil futures increasing by 1.72% to $63.21 per barrel [5] - Several companies announced significant developments, including a change in controlling shareholder for Jiatang and a fundraising plan for Xuguang Electronics [5]

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stocks were headed lower on Tuesday with the selloff in technology dragging down the S & P 500 by more than 1% and the Nasdaq by roughly 2%. As the market struggles with who will be the software losers from AI, the wreckage was also spilling over into private credit managers and business development companies with investments in software ...

Founded in 1876, Indianapolis, Indiana-based Eli Lilly and Company (LLY) discovers, develops, and markets human pharmaceuticals in the United States and internationally. The company has a market capitalization of $980.5 billion and boasts a diversified product profile, including a solid lineup of new, successful drugs. Shares of the healthcare giant have outperformed the broader market over the past year, but have underperformed in 2026. LLY stock has grown 28.7% over the past 52 weeks and has declined 2 ...

Eli Lilly and Co. (NYSE:LLY) is set to report fourth-quarter earnings on Feb. 4 before the opening bell, with Wall Street forecasting a significant revenue beat driven by its blockbuster weight-loss and diabetes drugs.While topline expectations are high, surging research costs could challenge the company's ability to hit ambitious profit targets.Revenue Expectations Vs. GuidanceAnalysts project fourth-quarter revenue of $17.90 billion, as per Benzinga, a figure that exceeds the implied ceiling of management ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s recent game plan. Cramer highlighted what “drives the stock,” as he remarked: Wednesday morning, Eli Lilly reports. Its earnings haven’t been the propellant here. What drives the stock are new reports on GLP-1 clinical trials. But Lilly could announce some new data, and that could get the stock rolling. Stock market data. Photo by Alesia Kozik on Pexels Eli Lilly and Company (NYSE:LLY) develops and markets medicines for diabetes, ob ...

Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to invest in. Eli Lilly and Company (NYSE:LLY) announced on January 30 significant plans to invest over $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania, which would function as the company’s newest injectable medicine and device manufacturing facility, producing next-generation weight-loss therapies. These include retatrutide, a first-in-class investigational GIP, GLP-1, and glucagon triple h ...

好的，各位投资人，晚上好，然后欢迎参加我们的医药每周谈第 236 期，关于 GP MOOC 2026 的海外公司的一个进展。然后我是中银建投医药分析师徐颖翔。然后就是关于整个 Gilead 海外公司的一个情况吧。我们可以看得出来，在整个基于摩根这个期间的话，海外 的药企主要就是在一个专利悬崖的一个压力下面，是加速转型与和与技术兑现。大部分跨 国药企的话，是通过一个大规模的 BD 和并购来平滑自己重磅产品专利的到期的一个销售 冲击。包括默沙东规划 700 亿美元的一个新的产品组合，BMS 的话这几年也完成了 300 亿美元的一个并购交易，阿斯利康的话也是目标在 2030 年能够实现一个 800 亿美元的一 个营收。 因此这几年的话，整个受并购与 BD 还是各家跨国药企最重要的一个战略布局的一个方向， 主要也就是为了应对专利悬崖，同时聚焦高确定性的资产，以及技术平台的一个补强。另 一方面的话，也是整个 AI，从工具也上升到了一个制药的一个核心生产力。成为整个制药 行业的一个核心的驱动，驱动力之一。多家跨国药企，包括礼来、阿斯利康、赛诺菲，都 在 GD Morgan 期间。通过与英伟达以及各种其他的 AI 公司达成 ...